Log in | Register

FTC Testifies Before House Judiciary Subcommittee on Agency's Work to Promote Competition and Benefit Consumers

For the latest pharmaceutical news and updates - Sign up now!
Loading...

In testimony today before a U.S. House of Representatives Judiciary Subcommittee, the Federal Trade Commission detailed its work to promote competition and benefit consumers, including preventing anticompetitive mergers, restricting "pay-for-delay" pharmaceutical agreements that increase prescription drug costs, stopping anticompetitive hospital mergers, and promoting competition in the high-technology and energy markets.

Testifying on behalf of the Commission before the Subcommittee on Intellectual Property, Competition, and the Internet, FTC Chairman Jon Leibowitz told the Subcommittee that competitive markets are the foundation of the U.S. economy, and effective antitrust enforcement is essential for those markets to function well.

"Vigorous competition promotes economic growth by keeping prices down, expanding output and the variety of choices available to consumers, and promoting innovation," Leibowitz said. "The FTC has jurisdiction over a wide swath of the economy, so we focus on sectors where our actions will do the greatest good for the greatest number of consumers, including energy, technology, and, of course, health care."

The FTC's competition work falls into three broad categories: merger review, investigations of anticompetitive conduct, and competition policy analysis. According to the testimony, one of the FTC's top competition priorities remains ending anticompetitive pay-for-delay agreements between brand-named drug companies and their generic competitors. These anticompetitive agreements keep low-cost generic drugs off the market and impose substantial costs on consumers, businesses, taxpayers, and government.

The testimony also outlines the FTC's recent work to stop anticompetitive health care mergers. In particular, the FTC has redoubled its efforts to prevent anticompetitive hospital mergers, and the Commission currently has three legal challenges to proposed hospital mergers pending in administrative litigation.

The testimony also addresses antitrust oversight in technology industries, including how competition law can keep up with a rapidly evolving marketplace. It concludes by describing the FTC's work in monitoring energy markets and outlining the Commission's international competition efforts, as well as consumer protection highlights such as the agency's continued focus on protecting financially distressed consumers and ensuring privacy protections.

The Commission vote approving the testimony and its inclusion in the formal record was 4-0.

The FTC's Bureau of Competition works with the Bureau of Economics to investigate alleged anticompetitive business practices and, when appropriate, recommends that the Commission take law enforcement action. To inform the Bureau about particular business practices, call 202-326-3300, send an e-mail to antitrust@ftc.gov, or write to the Office of Policy and Coordination, Bureau of Competition, Federal Trade Commission, 601 New Jersey Ave., Room 7117, Washington, DC 20580. To learn more about the Bureau of Competition, read Competition Counts. Like the FTC on Facebook and follow us on Twitter..

MEDIA CONTACT:
Mitchell J. Katz
Office of Public Affairs

202-326-2161
(FTC File No. P859910)
(Antitrust Testimony.final.wpd)

SOURCE

Join the Discussion
Rate Article:  Average 0 out of 5
register or log in to comment on this article!

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

Blogs

The Tale of Two Deviations

The Tale of Two Deviations

Apr 23 | The QA Pharm

It stands to reason that pharmaceutical companies in compliance trouble also have problems with their Deviation Management and Corrective and Preventive Action (CAPA) System(s).

Can the Combination of Creative Destruction and “Steve Jobs’ Traits” Lead to a “Pharma QbD Spring”?

Can the Combination of Creative Destruction and “Steve Jobs’ Traits” Lead to a “Pharma QbD Spring”?

Apr 16 | Girish Malhotra, PE, President, EPCOT International

The answer is an unequivocal yes but we need some outsiders who can conspire with the insiders who will be the flag bearers within the companies. Outsiders can be the counsels/co-conspirators to the insiders for the coup d'etat.

Multimedia

Merck - 2012 Facility of the Year Award - Facility Integration

Merck - 2012 Facility of the Year Award - Facility Integration

May 14 | Video

Brian Morrissey, Senior Project Engineer, Merck Manufacturing Division, talks to Pharmaceutical Processing's Editor In Chief Mike Auerbach during INTERPHEX 2012 about the company's Vaccine Bulk Manufacturing Facility Program of Projects. The facility has won the Facility Integration award in the 2012 Facility of the Year Award competition sponsored by ISPE, INTERPHEX and Pharmaceutical Processing magazine.

Medicine from a Vending Machine?

Medicine from a Vending Machine?

May 3 | Video

A Chinese company is pushing for acceptance of traditional Chinese medicine with a machine that can dispense herbs.

Taking Precautions to Prevent Contagion

Taking Precautions to Prevent Contagion

Apr 29 | Video

With the recent outbreak of viruses such as SARS, bird flu and swine flu, officials and travelers are being extra careful about preventing the illnesses from being transmitted.

Measles Infections on the Rise in the U.S.

Measles Infections on the Rise in the U.S.

Apr 20 | Video

Just over a decade ago, U.S. health officials believed measles would be eradicated, but according to a new report from the Centers for Disease Control, infections are back and the numbers are growing. Dr. Nancy Snyderman, NBC's Chief Medical Editor reports.

Top Stories and Headlines
EVERY DAY!

FREE Email Newsletter